CureVac: ‘We enter 2023 as a competitive player in the development of mRNA therapies’
Germany's CureVac announced positive preliminary data today from its ongoing Phase 1 clinical programs in COVID-19 and seasonal flu.
Archives for January 6, 2023
Moderna and CytomX partner up on mRNA-based conditionally activated therapeutics
Moderna and CytomX Therapeutics have announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies using Moderna's mRNA technologies and CytomX's Probody therapeutic platform.
BioNTech and UK government set out strategic partnership for personalized mRNA cancer immunotherapies
BioNTech and the UK government have signed a wide-reaching Memorandum of Understanding (MoU): with one of the goals to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030.
Synaffix secures additional ADC technology licensing deals
Synaffix, a Netherlands based company providing clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has signed off on two new licensing deals this week.